Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities

Nicolette Stogios; Margaret K. Hahn; Yona Lunsky; Pushpal Desarkar; Sri Mahavir Agarwal

doi:10.1503/jpn.220200

Article Information

vol. 48 no. 2 E99-E101

DOI

https://doi.org/10.1503/jpn.220200

PubMed

36918196

History

Published online March 14, 2023.

© 2023 CMA Impact Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Author Information

Nicolette Stogios, HBSc,
Margaret K. Hahn, MD, PhD,
Yona Lunsky, PhD,
Pushpal Desarkar, MD,
Sri Mahavir Agarwal, MBBS, PhD

From the Institute of Medical Science, University of Toronto, Toronto, Ont. (Stogios, Hahn, Desarkar, Agarwal); the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ont. (Stogios, Hahn, Agarwal); the Department of Psychiatry, University of Toronto, Toronto, Ont. (Hahn, Lunsky, Desarkar, Agarwal); the Banting and Best Diabetes Centre, University of Toronto, Toronto, Ont. (Hahn, Agarwal); the Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Lunsky, Desarkar)